United StatesBreaking News

Air Products (NYSE:APD) announced it will not proceed with the Louisiana Clean Energy Complex, citing expected financial returns not meeting the company’s strict criteria.

FAST TRACK GROUP (NASDAQ:FTRK) reported audited financial results for the fiscal year ended February 28, 2026, showing total revenue of $1.7 million, a 112% increase from the prior year.

Flash Sports & Media Holdings (NASDAQ:FLZH) signed a confidential, non-binding letter of intent to acquire a 51% controlling interest in Dubai-based hospitality group Nooa.

The U.S. Food and Drug Administration selected seven companies for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities.

PowerBank (NASDAQ:PBK) announced that its subsidiary, Abundant Solar Power, has signed an operations and maintenance agreement with Honeywell for a 21 MW portfolio of three New York community solar projects.

Bank of England Deputy Governor Sarah Breeden says the use of autonomous artificial intelligence agents "could amplify volatility in stress" in financial markets and may need tighter regulation. She speaks at the European Central Bank's annual symposium in Sintra, Portugal.

Unicycive Therapeutics (NASDAQ:UNCY) said the U.S. Food and Drug Administration issued a Complete Response Letter for its resubmitted new drug application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.

Patrick Industries (NASDAQ:PATK) and LCI Industries (NYSE:LCII) have entered into a definitive agreement to combine in an all-stock merger.

GreenTree Hospitality (NYSE:GHG) reported first quarter 2026 total revenues of RMB227.7 million, equivalent to US$33 million, a decrease of 14% year over year.

AC Immune (NASDAQ:ACIU) reported 12-month interim data from the Phase 1b/2 ABATE trial of ACI-24 in 74 patients with prodromal Alzheimer’s disease across cohorts AD1-AD3.

HeartBeam (NASDAQ:BEAT) announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.

Pasithea Therapeutics (NASDAQ:KTTA) reported positive interim Phase 1 clinical trial results for PAS-004, an oral MEK inhibitor being tested in advanced MAPK pathway-driven solid tumors, including patients previously treated with MEK and BRAF inhibitors.